VYGR - Voyager Therapeutics Inc Stock Price, Fair Value and News

8.44USD-0.19 (-2.20%)Market Closed

Market Summary

USD8.44-0.19

Market Closed

-2.20%

VYGR Alerts

Big fall in Revenue (Y/Y)

Big fall in earnings (Y/Y)
Losses in recent quarter

VYGR Stock Price

View Fullscreen

VYGR RSI Chart

VYGR Valuation

Market Cap

459.1M

Price/Earnings (Trailing)

-150.82

Price/Sales (Trailing)

3.86

EV/EBITDA

148.05

Price/Free Cashflow

55.76

VYGR Price/Sales (Trailing)

VYGR Profitability

EBT Margin

-1.95%

Return on Equity

-0.89%

Return on Assets

-0.65%

Free Cashflow Yield

1.79%

VYGR Fundamentals

VYGR Revenue

Revenue (TTM)

119.0M

Rev. Growth (Yr)

-87.04%

Rev. Growth (Qtr)

-78.35%

VYGR Earnings

Earnings (TTM)

-3.0M

Earnings Growth (Yr)

-109.13%

Earnings Growth (Qtr)

-120.09%

Breaking Down VYGR Revenue

Last 30 days

9.0%

Last 90 days

11.8%

Trailing 12 Months

-31.2%

How does VYGR drawdown profile look like?

VYGR Financial Health

Current Ratio

5.64

VYGR Investor Care

Shares Dilution (1Y)

24.94%

Diluted EPS (TTM)

-0.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	119.0M	0	0	0
2023	93.2M	145.5M	197.7M	250.0M
2022	38.3M	39.2M	40.0M	40.9M
2021	159.6M	132.2M	15.9M	37.4M
2020	117.3M	99.9M	197.3M	171.1M
2019	11.9M	55.4M	73.7M	104.4M
2018	9.6M	11.0M	12.0M	7.6M
2017	10.9M	8.3M	6.2M	10.1M
2016	19.6M	18.4M	16.8M	14.2M
2015	0	0	0	17.3M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Voyager Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 02, 2024	sandrock alfred	sold	-119,454	9.86	-12,115	president and ceo
Apr 02, 2024	swartz robin	sold	-13,407	9.88	-1,357	chief operating officer
Apr 01, 2024	ferguson toby	acquired	-	-	105,000	chief medical officer
Feb 21, 2024	carter todd alfred	sold	-25,136	7.47	-3,365	chief scientific officer
Feb 21, 2024	sandrock alfred	sold	-97,226	7.46	-13,033	president and ceo
Feb 21, 2024	pfreundschuh peter p.	sold	-28,079	7.46	-3,764	chief financial officer
Feb 21, 2024	swartz robin	sold	-29,546	7.45	-3,966	chief operating officer
Feb 20, 2024	carter todd alfred	sold	-4,623	7.68	-602	chief scientific officer
Feb 09, 2024	carter todd alfred	acquired	-	-	38,500	chief scientific officer
Feb 09, 2024	swartz robin	acquired	-	-	50,000	chief operating officer

Which funds bought or sold VYGR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	new	-	386,542	386,542	-%
May 16, 2024	Virtus Investment Advisers, Inc.	new	-	117,753	117,753	0.08%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-24.31	-7,284	36,840	-%
May 15, 2024	DEUTSCHE BANK AG\	added	9.3	114,220	669,454	-%
May 15, 2024	Woodline Partners LP	new	-	2,793,000	2,793,000	0.03%
May 15, 2024	Ikarian Capital, LLC	reduced	-40.87	-897,654	1,683,780	0.18%
May 15, 2024	Steward Partners Investment Advisory, LLC	unchanged	-	348	3,724	-%
May 15, 2024	BOOTHBAY FUND MANAGEMENT, LLC	reduced	-40.87	-196,621	368,834	0.01%
May 15, 2024	Voya Investment Management LLC	reduced	-23.47	-17,448	94,534	-%
May 15, 2024	DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	added	106	167,257	297,967	-%

Are Funds Buying or Selling VYGR?

Are funds buying VYGR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VYGR

No. of Funds

Unveiling Voyager Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.63%	4,236,000	SC 13G/A
Feb 14, 2024	third rock ventures iii, l.p.	0%	0	SC 13G/A
Feb 13, 2024	vanguard group inc	5.75%	2,529,668	SC 13G/A
Jan 29, 2024	blackrock inc.	6.0%	2,632,679	SC 13G
Feb 24, 2023	neurocrine biosciences inc	19.9%	8,575,316	SC 13D/A
Feb 14, 2023	armistice capital, llc	8.80%	3,396,000	SC 13G
Feb 14, 2023	third rock ventures iii, l.p.	14.1%	5,428,933	SC 13G/A
Feb 09, 2023	vanguard group inc	5.06%	1,955,172	SC 13G/A
Jan 13, 2023	ecor1 capital, llc	9.98%	3,851,507	SC 13G/A
Apr 26, 2022	ecor1 capital, llc	11.1%	4,276,507	SC 13G/A

Recent SEC filings of Voyager Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	8-K	Current Report
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 02, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Voyager Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.57	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Voyager Therapeutics Inc News

Latest updates

Voyager Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-78.3%	19,500	90,061	4,614	4,853	150,480	95,783	41,086	36,749	32,411	28,074	1,482	1,357	6,501	6,537	117,843	28,681	18,067	32,674	20,433	46,087	5,197
Operating Expenses	-0.8%	35,699	35,998	34,121	30,279	27,596	23,013	26,644	20,079	22,008	22,372	26,628	29,942	32,090	30,266	33,316	37,662	42,500	46,442	38,240	36,898	34,490
S&GA Expenses	-100.0%	-	10,242	8,258	8,294	9,028	8,462	7,307	7,552	7,659	8,351	8,714	10,437	9,744	8,270	8,277	8,239	10,206	9,891	8,463	8,322	9,659
R&D Expenses	5.2%	27,092	25,756	25,863	21,985	18,568	14,551	19,337	12,527	14,349	14,021	17,914	19,505	22,346	21,997	25,039	29,423	32,294	36,551	29,777	28,576	24,831
EBITDA Margin	-96.8%	0.02*	0.55*	0.29*	0.69*	1.12*	-0.98*	-1.61*	-1.65*	-1.68*	-1.76*	2.61*	0.31*	-	-	-	-	-	-	-	-	-
Income Taxes	-98.3%	14.00	822	-177	59.00	704	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-119.8%	-11,316	57,217	-26,078	-22,149	124,748	-23,610	17,624	-19,087	-21,319	-	-	-	-	-	-	-	-	-12,574	-15,006	11,153	-27,170
EBT Margin	-103.7%	-0.02*	0.53*	0.27*	0.66*	1.07*	-1.13*	-1.78*	-1.82*	-1.86*	-1.90*	2.31*	0.28*	-	-	-	-	-	-	-	-	-
Net Income	-120.1%	-11,330	56,395	-25,901	-22,208	124,044	-23,626	17,624	-19,087	-21,319	5,709	-25,137	-30,120	-21,649	-15,926	85,611	-8,681	-24,263	-12,574	-15,006	11,153	-27,170
Net Income Margin	-104.8%	-0.03*	0.53*	0.26*	0.66*	1.06*	-1.13*	-0.43*	-1.53*	-1.85*	-1.90*	-5.85*	0.14*	-	-	-	-	-	-	-	-	-
Free Cashflow	331.0%	56,626	-24,515	-21,833	-2,045	123,056	-13,177	-16,484	-19,727	34,388	10,848	-21,369	-22,944	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	33.7%	470	351	295	316	336	159	182	189	224	194	185	209	238	262	270	297	323	355	376	389	411
Current Assets	28.0%	409	320	262	282	303	124	147	152	171	137	126	149	176	198	216	247	272	305	328	341	365
Cash Equivalents	112.1%	146	69.00	65.00	244	268	99.00	98.00	80.00	132	117	113	120	118	106	149	146	165	87.00	83.00	81.00	113
Net PPE	5.4%	17.00	16.00	17.00	17.00	17.00	18.00	18.00	19.00	19.00	22.00	23.00	24.00	25.00	25.00	23.00	20.00	19.00	18.00	15.00	14.00	13.00
Liabilities	12.0%	129	115	118	117	119	100	103	129	148	99.00	97.00	98.00	102	107	104	221	243	255	268	270	311
Current Liabilities	12.5%	73.00	65.00	62.00	45.00	20.00	73.00	73.00	98.00	102	51.00	27.00	25.00	25.00	27.00	42.00	68.00	73.00	76.00	80.00	69.00	59.00
Shareholder's Equity	44.2%	341	236	176	199	217	59.00	80.00	60.00	76.00	95.00	87.00	111	136	154	166	77.00	80.00	100	108	118	101
Retained Earnings	-4.3%	-272	-261	-317	-291	-269	-393	-369	-387	-368	-347	-352	-327	-297	-275	-259	-345	-336	-312	-300	-285	-296
Additional Paid-In Capital	23.4%	614	498	494	491	487	453	450	448	445	442	440	438	434	430	426	422	416	412	408	403	397
Shares Outstanding	23.3%	54.00	44.00	44.00	44.00	43.00	39.00	39.00	38.00	38.00	38.00	38.00	38.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	489	-	-	-	114	-	-	-	103	-	-	-	292	-	-	-	686	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	347.3%	58,767	-23,760	-21,051	-835	123,565	-12,244	-16,206	-18,485	34,426	11,195	-20,709	-22,717	-21,294	-21,977	-24,740	-21,201	-28,798	-23,360	-21,579	-31,557	125,162
Share Based Compensation	17.3%	3,573	3,045	2,878	2,672	2,558	2,346	2,189	2,490	2,319	1,654	2,078	3,991	3,601	3,502	3,532	3,860	4,040	3,520	3,349	5,253	3,518
Cashflow From Investing	-458.0%	-96,065	26,833	-158,304	-24,663	14,491	14,067	34,722	-36,130	-19,998	-5,464	14,340	22,405	34,625	-21,516	27,356	-1,838	108,993	26,462	22,610	-2,888	-136,661
Cashflow From Financing	24433.9%	112,856	460	331	1,548	31,306	276	15.00	807	12.00	227	-	357	28.00	486	510	2,133	34.00	300	1,724	1,069	77,901

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VYGR Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
Collaboration revenue	$ 19,516	$ 150,480
Operating expenses:
Research and development	27,092	18,568
General and administrative	8,607	9,028
Total operating expenses	35,699	27,596
Operating (loss) income	(16,183)	122,884
Other income:
Interest income	4,867	1,864
Total other income	4,867	1,864
(Loss) income before income taxes	(11,316)	124,748
Income tax provision	14	704
Net (loss) income	(11,330)	124,044
Other comprehensive (loss) income:
Net unrealized (loss) gain on available-for-sale securities	(458)	87
Total other comprehensive (loss) income	(458)	87
Comprehensive (loss) income	$ (11,788)	$ 124,131
Net (loss) income per share, basic	$ (0.20)	$ 3.05
Net (loss) income per share, diluted	$ (0.20)	$ 2.94
Weighted-average common shares outstanding, basic	57,117,046	40,632,087
Weighted-average common shares outstanding, diluted	57,117,046	42,161,326

VYGR Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 143,078	$ 68,802
Marketable securities, current	256,490	162,073
Accounts receivable	837	80,150
Related party collaboration receivable	2,620	3,341
Prepaid expenses and other current assets	6,112	5,318
Total current assets	409,137	319,684
Property and equipment, net	17,381	16,494
Deposits and other non-current assets	2,890	1,593
Marketable securities, non-current	980
Operating lease, right-of-use assets	39,204	13,510
Total assets	469,592	351,281
Current liabilities:
Accounts payable	7,579	1,604
Accrued expenses	7,595	16,823
Other current liabilities	5,940	3,200
Deferred revenue, current	51,439	42,881
Total current liabilities	72,553	64,508
Deferred revenue, non-current	13,157	32,359
Other non-current liabilities	42,996	18,094
Total liabilities	128,706	114,961
Commitments and contingencies (see note 7)
Stockholders' equity:
Preferred stock, $0.001 par value: 5,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.001 par value: 120,000,000 shares authorized at March 31, 2024 and December 31, 2023; 54,318,133 and 44,038,333 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	54	44
Additional paid-in capital	613,850	497,506
Accumulated other comprehensive loss	(506)	(48)
Accumulated deficit	(272,512)	(261,182)
Total stockholders' equity	340,886	236,320
Total liabilities and stockholders' equity	$ 469,592	$ 351,281

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease. In addition, the company develops research program for the treatment of Huntington's disease. It has collaboration and license agreements with Neurocrine Biosciences, Inc.; Pfizer Inc.; and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
WEBSITE	voyagertherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	125

Voyager Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Voyager Therapeutics Inc? What does VYGR stand for in stocks?

VYGR is the stock ticker symbol of Voyager Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Voyager Therapeutics Inc (VYGR)?

As of Fri May 17 2024, market cap of Voyager Therapeutics Inc is 459.08 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VYGR stock?

You can check VYGR's fair value in chart for subscribers.

What is the fair value of VYGR stock?

You can check VYGR's fair value in chart for subscribers. The fair value of Voyager Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Voyager Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VYGR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Voyager Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether VYGR is over valued or under valued. Whether Voyager Therapeutics Inc is cheap or expensive depends on the assumptions which impact Voyager Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VYGR.

What is Voyager Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, VYGR's PE ratio (Price to Earnings) is -150.82 and Price to Sales (PS) ratio is 3.86. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VYGR PE ratio will change depending on the future growth rate expectations of investors.